Ver­tex gets more pre­cise with Ar­bor in ex­pand­ed gene edit­ing pact

Feng Zhang’s Ar­bor Biotech­nolo­gies is ex­pand­ing its al­liance with Ver­tex Phar­ma­ceu­ti­cals, but is stay­ing mum on fi­nan­cials this time around.

The CRISPR gene edit­ing start­up, which has been rel­a­tive­ly qui­et aside from part­ner­ship and cap­i­tal-rais­ing news since its March 2018 un­veil­ing, is pro­vid­ing its Boston part­ner with ac­cess to pre­ci­sion edit­ing tech­nol­o­gy for in vi­vo ge­net­ic med­i­cines for “up to three dis­eases.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER